

## 2 Contents

|    |   |    |   |
|----|---|----|---|
| 17 | Consensus 19: Increasing safety during Vascular Venous Malformation treatment with Foam Sclerotherapy   | 18 | Description 20: Repeated dorsiflexion of the foot after Foam Sclerotherapy                      |
| 18 | Consensus 20: Known asymptomatic Patent Foramen Ovale   | 19 | Description 21: Known symptomatic Patent Foramen Ovale  |
| 19 | Consensus 21: Looking for a Patent Foramen Ovale before Foam Sclerotherapy                              | 19 | Description 22: History of migraine   |
| 20 | Consensus 22: Looking for thrombophilia before Foam Sclerotherapy                                       | 19 | Description 23: History of thromboembolism  |
| 20 | Consensus 23: Use of low molecular weight heparin (LMWH) prophylaxis                                    | 20 | Description 24: High risk of thromboembolism  |
| 22 | Consensus 24: Patient information concerning risks and side effects                                     | 20 | Description 25: Known thrombophilia   |
| 22 | Consensus 25: Patient information concerning efficacy   | 20 | Description 26: Other relative contraindications  |
| 23 | Consensus 26: Duplex guidance during Foam Sclerotherapy   | 20 | Description 27: Other absolute contraindications  |
| 23 | Consensus 27: Duplex criteria to evaluate the effects of Foam Sclerotherapy                             | 21 | Description 28: Compression after Foam Sclerotherapy  |
| 24 | Consensus 28: Definition / grading of therapeutic effects of Foam Sclerotherapy                         | 21 | Description 29: Compression material after Foam Sclerotherapy                                   |
| 25 | Consensus 29: Clot removal after Foam Sclerotherapy   | 21 | Description 30: Time for applying compression   |
|    | <b>Descriptions</b>   | 22 | Description 31: Patient information concerning safety   |
| 5  | Description 1: Access material for Foam Sclerotherapy   | 23 | Description 32: Necessity of a blocking balloon for endovenous long-catheter Foam Sclerotherapy |
| 6  | Description 2: Access material (needles)  | 23 | Description 33: The role of Duplex Ultrasound in pre-treatment diagnosis                        |
| 7  | Description 3: Access location for treatment of Tributaries and Recurrent Varicose Veins                | 25 | Description 34: The role of Duplex Ultrasound after Foam Sclerotherapy                          |
| 10 | Description 4: Concentrations of Polidocanol / Diameter   |    |   |
| 10 | Description 5: Concentrations of STS / Indication   |    |   |
| 10 | Description 6: Concentrations of STS / Diameter   |    |   |
| 13 | Description 7: Average foam volume per session  |    |   |
| 13 | Description 8: Maximum foam volumes per session for C <sub>1</sub> - and C <sub>2</sub> -varicose veins |    |   |
| 13 | Description 9: Limitation of volume or concentration during Foam Sclero-therapy                         |    |   |
| 14 | Description 10: Limitation of foam volume per session   |    |   |
| 14 | Description 11: Indication of initial efficacy by the occurrence of vasospasm                           |    |   |
| 14 | Description 12: Indication of a sufficient foam volume or concentration by the occurrence of vasospasm  |    |   |
| 14 | Description 13: Choice of injection volume determined by the occurrence of vasospasm                    |    |   |
| 15 | Description 14: Procedures after non-occurrence of vasospasm  |    |   |
| 15 | Description 15: Procedures after unsuccessful treatment at the first follow-up visit                    |    |   |
| 16 | Description 16: Increasing safety during GSV treatment with Foam Sclerotherapy                          |    |   |
| 17 | Description 17: Leg elevation during and/or after Foam Sclerotherapy                                    |    |   |
| 17 | Description 18: Upper body position during Foam Sclerotherapy   |    |   |
| 18 | Description 19: Compression of junctions during Foam Sclerotherapy                                      |    |   |